Dup15q Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Duplication syndrome on chromosome 15q11.2-13.1, also known as Dup15q Syndrome, results from extra genetic material in the 15q11.2-13.1 region, sometimes referred to as the Prader-Willi/Angelman critical region (PWACR). This syndrome is clinically identifiable and is characterized by symptoms such as hypotonia, motor delays, intellectual disability, autism spectrum disorder (ASD), and epilepsy, including infantile spasms. In rare cases, maternal Dup15q may also lead to psychosis or unexplained death. Approximately 30 percent of individuals with Dup15q Syndrome have strabismus (crossed eyes), and about 20-30 percent experience growth-related issues resulting in smaller stature. Hypotonia tends to improve with age, and in some cases, it may progress to hypertonia, especially in the lower legs. Other associated problems include reduced pain sensitivity, scoliosis, recurrent childhood respiratory infections, precocious puberty, menstrual irregularities in females, minor genital abnormalities in males, overeating, and excessive weight gain.
·
The prevalence of Dup15q Syndrome remains
uncertain but may affect as many as 1 in 5,000 individuals in the general
population and is believed to be roughly ten times more common in people with
ASD or intellectual disability.
Thelansis’s
“Dup15q Syndrome Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Dup15q
Syndrome treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights of Dup15q Syndrome
across 8 MM market from the centre of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm, and Unmet
needs.
Dup15q
Syndrome Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Dup15q
Syndrome, Dup15q Syndrome market outlook, Dup15q
Syndrome competitive landscape, Dup15q
Syndrome market forecast, Thelansis, Primary market
research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment